Autophagy inhibitors for cancer therapy: Small molecules and nanomedicines

被引:35
作者
Chen, Jian-Li [1 ]
Wu, Xuan [1 ]
Yin, Dan [1 ]
Jia, Xiao-Hui [1 ]
Chen, Xu [1 ]
Gu, Ze-Yun [1 ]
Zhu, Xiao-Ming [1 ]
机构
[1] Macau Univ Sci & Technol, Macau Inst Appl Res Med & Hlth, State Key Lab Qual Res Chinese Med, Macau, Peoples R China
关键词
Autophagy inhibitors; Nanomaterials; Cancer; Chemotherapy; Chemosensitization; Nanomedicines; PHASE-I TRIAL; SILVER NANOPARTICLES; ANTICANCER ACTIVITY; INDUCED APOPTOSIS; DELIVERY-SYSTEM; GRAPHENE OXIDE; CELLS; LYSOSOME; DRUG; FLUX;
D O I
10.1016/j.pharmthera.2023.108485
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Autophagy is a conserved process in which the cytosolic materials are degraded and eventually recycled for cellular metabolism to maintain homeostasis. The dichotomous role of autophagy in pathogenesis is complicated. Accumulating reports have suggested that cytoprotective autophagy is responsible for tumor growth and progression. Autophagy inhibitors, such as chloroquine (CQ) and hydroxychloroquine (HCQ), are promising for treating malignancies or overcoming drug resistance in chemotherapy. With the rapid development of nanotechnology, nanomaterials also show autophagy-inhibitory effects or are reported as the carriers delivering autophagy inhibitors. In this review, we summarize the small-molecule compounds and nanomaterials inhibiting autophagic flux as well as the mechanisms involved. The nanocarrier-based drug delivery systems for autophagy inhibitors and their distinct advantages are also described. The progress of autophagy inhibitors for clinical applications is finally introduced, and their future perspectives are discussed.
引用
收藏
页数:19
相关论文
共 236 条
  • [11] A randomized, double-blind, window of opportunity trial evaluating the effects of chloroquine in breast cancer patients
    Arnaout, Angel
    Robertson, Susan J.
    Pond, Gregory R.
    Lee, Hoyun
    Jeong, Ahwon
    Ianni, Luisa
    Kroeger, Lynne
    Hilton, John
    Coupland, Stuart
    Gottlieb, Chloe
    Hurley, Bernard
    McCarthy, Anne
    Clemons, Mark
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2019, 178 (02) : 327 - 335
  • [12] Modulation of autophagy: A phase II study of vorinostat (VOR) plus hydroxychloroquine (HCQ) vs regorafenib (RGF) in chemo-refractory metastatic colorectal cancer (mCRC).
    Arora, Sukeshi Patel
    Tenner, Laura LaNiel
    Sarantopoulos, John
    Morris, Jay Larry
    Longoria, Lisa
    Liu, Qianqian
    Michalek, Joel
    Mahalingam, Devalingam
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [13] Deletion of the SNARE vti1b in mice results in the loss of a single SNARE partner, syntaxin 8
    Atlashkin, V
    Kreykenbohm, V
    Eskelinen, EL
    Wenzel, D
    Fayyazi, A
    von Mollard, GF
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2003, 23 (15) : 5198 - 5207
  • [14] CdTe quantum dots trigger oxidative stress and endoplasmic reticulum stress-induced apoptosis and autophagy in rat Schwann cell line RSC96
    Bai, Changcun
    Yao, Yongshuai
    Wang, Zhihui
    Huang, Xiaoquan
    Wei, Tingting
    Zou, Lingyue
    Liu, Na
    Zhang, Ting
    Tang, Meng
    [J]. JOURNAL OF APPLIED TOXICOLOGY, 2022, 42 (12) : 1962 - 1977
  • [15] mTORC2: The other mTOR in autophagy regulation
    Ballesteros-Alvarez, Josue
    Andersen, Julie K.
    [J]. AGING CELL, 2021, 20 (08)
  • [16] Targeting quiescent leukemic stem cells using second generation autophagy inhibitors
    Baquero, Pablo
    Dawson, Amy
    Mukhopadhyay, Arunima
    Kuntz, Elodie M.
    Mitchell, Rebecca
    Olivares, Orianne
    Lanniciello, Angela
    Scott, Mary T.
    Dunn, Karen
    Nicastri, Michael C.
    Winkler, Jeffrey D.
    Michie, Alison M.
    Ryan, Kevin M.
    Halsey, Christina
    Gottlieb, Eyal
    Keaney, Erin P.
    Murphy, Leon O.
    Amaravadi, Ravi K.
    Holyoake, Tessa L.
    Helgason, G. Vignir
    [J]. LEUKEMIA, 2019, 33 (04) : 981 - 994
  • [17] Regulation of mTORC1 by amino acids
    Bar-Peled, Liron
    Sabatini, David M.
    [J]. TRENDS IN CELL BIOLOGY, 2014, 24 (07) : 400 - 406
  • [18] Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells
    Bellodi, Cristian
    Lidonnici, Maria Rosa
    Hamilton, Ashley
    Helgason, G. Vignir
    Soliera, Angela Rachele
    Ronchetti, Mattia
    Galavotti, Sara
    Young, Kenneth W.
    Selmi, Tommaso
    Yacobi, Rinat
    Van Etten, Richard A.
    Donato, Nick
    Hunter, Ann
    Dinsdale, David
    Tirro, Elena
    Vigneri, Paolo
    Nicotera, Pierluigi
    Dyer, Martin J.
    Holyoake, Tessa
    Salomoni, Paolo
    Calabretta, Bruno
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2009, 119 (05) : 1109 - 1123
  • [19] Safety and Biologic Response of Pre-operative Autophagy Inhibition in Combination with Gemcitabine in Patients with Pancreatic Adenocarcinoma
    Boone, Brian A.
    Bahary, Nathan
    Zureikat, Amer H.
    Moser, A. James
    Normolle, Daniel P.
    Wu, Wen-Chi
    Singhi, Aatur D.
    Bao, Phillip
    Bartlett, David L.
    Liotta, Lance A.
    Espina, Virginia
    Loughran, Patricia
    Lotze, Michael T.
    Zeh, Herbert J., III
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (13) : 4402 - 4410
  • [20] Briceno Eduardo, 2003, Neurosurg Focus, V14, pe3